Story thread · 2 reports / 2 sources
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
financialpost.com · 4h · first report
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027 The Company has voluntarily initiated a temporary pause of enrollment […]
The coverage
- Xenon drops after pausing enrollment in azetukalner studies for depression
seekingalpha.com · 4h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.